ERN-Clinical Guidelines Programme Launched
On 6th February, a new 4-year project was launched “to provide technical assistance to the ERNs for the development, appraisal and implementation of Clinical Practice Guidelines (CPGs) and Clinical Decision Support Tools (CDSTs)”. The need for such an initiative was identified by the Working Group on Knowledge Generation, a group made up of representatives of ERNs and Member States. The kick-off was attended by members of the European Reference Networks (ERN) and the European Commission as well as the members of the tender-winning consortium headed by Fundación Progreso y Salud.
The project will help to harmonise CPG and CDST methodologies between ERNs and aims to develop 48 new CPGs and the adaptation of 120 existing CPGs to specific rare diseases. Between early 2018 and mid 2019 the 24 ERNs have adopted more than 650 CPGs and CDMTs, written 11 new CPGs and 54 new CDMTs. However, organisational approaches are different within the ERNs, with some focused on the implementation or adaptation of decision-making tools, and others prioritising and planning future actions. ERNs have different needs: depending on the diseases they cover support may be needed to adapt tools, to disseminate them, or to imagine different decision-making tools when there is not enough evidence to develop CPGs.
Among the priorities of the project is a scoping of the current landscape, the development of a common methodology regarding decision-making tools, and training sessions to build the capacity of ERNs to produce their own decision-making tools. Per ERN, 2 new CPGs (48 new CPGs in total) and the review of 5 decision-making tools are expected.120 existing CPGs are also excepted to be adapted during the coming four years. The question of the copyright applied to existing CPGs developed by scientific societies was raised. Orphanet addressed the importance of avoiding duplication by taking into account the over 500 guidelines appraised and disseminated by Orphanet.
By harmonising approaches and providing technical support and capacity-building, the project will allow the rare disease health community to access average and reliable decision-making tools for rare diseases for a better access to treatments for patients, and an appropriate diagnosis.




